Early Functional Outcomes After Evolutionary Total Knee Arthroplasty

A Randomized Controlled Trial. Is New Always Better?

Sunil K. Panchani, MBChB(Hons), MSc(OrthEng), FRCS(Tr&Orth), Hiren M. Divecha, MBChB, BSc, MSc(OrthEng), FRCS(Tr&Orth), Rebecca Lafferty, BA, George Pavlou, MBChB, BSc, FRCS(Tr&Orth), Jez Oakley, MBChB, FRCS(Tr&Orth), Debbie Shaw, MBChB, BSc, FRCS(Tr&Orth), Amol Chitre, MBChB, FRCS(Tr&Orth), Henry Wynn Jones, MBChB, FRCS(Tr&Orth), Videsh Raut, MBChB, FRCS(Tr&Orth), Robert Smith, MBChB, FRCS(Tr&Orth), Anil Gambhir, MBChB, FRCS(Tr&Orth), and Tim Board, MBChB, BSc, MSc(OrthEng), FRCS(Tr&Orth), MD

Investigation performed at Wrightington Hospital, Wigan, United Kingdom

**Background:** Total knee replacement (TKR) designs continue to evolve with the aim of improving patient outcomes; however, there remains a significant patient dissatisfaction rate. We report the early functional outcomes of an evolutionary knee design in the context of a single-blinded, noninferiority, randomized controlled trial.

**Methods:** Patients were randomized to receive either the P.F.C. SIGMA or ATTUNE knee implant systems (DePuy Synthes). All implants were fixed-bearing, cruciate-retaining, and cemented constructs. Patients were assessed at baseline and 6 weeks, 3 months, and 1 year postoperatively using clinical and functional outcome measures, including range of motion, Oxford Knee Score (OKS), Oxford Knee Score-Activity and Participation Questionnaire (OKS-APQ), Patient Knee Implant Performance (PKIP) score, 5-Level EuroQol 5 Dimensions (EQ-5D-5L), and Short Form-36 outcome measures.

**Results:** There were 150 patients who underwent a surgical procedure (76 with the ATTUNE implant and 74 with the P.F.C. SIGMA implant), with 147 patients remaining at the final review. No differences were observed in any of the outcome measures between the groups at any time point. Tourniquet time was significantly shorter in the P.F.C. SIGMA arm ($p = 0.001$); however, this had no clinical impact on the OKS (analysis of covariance [ANCOVA] test) at the final review ($p = 0.825$). There was no difference in the numbers of patients achieving the minimal clinically important difference for the OKS between the groups ($p = 0.817$).

**Conclusions:** This trial did not show inferiority of the ATTUNE implant when compared with the P.F.C. SIGMA implant. The authors believe that implant innovation should continue and that modern implants should be introduced into the market following randomized controlled trials. Further work should assess the effect of non-implant-related factors on patient outcomes.

**Level of Evidence:** Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

Total knee arthroplasty (TKA) successfully reduces pain and improves quality of life in patients with primary knee osteoarthritis. In the United Kingdom in 2018, there were >90,000 TKAs performed, and this number is likely to rise over the coming years. However, there still remains up to a 20% dissatisfaction rate in patients who have normal postoperative investigations and no detectable pain generator. This has driven innovations in implant designs, materials, and knee kinematics understanding, with the hope of improving clinical outcomes.

The P.F.C. SIGMA system (DePuy Synthes) is the most widely used total knee replacement (TKR) design, with excellent survival and clinical outcomes. In 2013, DePuy Synthes introduced the ATTUNE knee system. A gradual reduction of the femoral radius, a deeper trochlear notch, and an improved inventory of implant sizes were hypothesized to improve knee kinematics, knee stability, and early patient outcomes. The aim of this study was to compare the early patient-reported functional and clinical outcomes between these 2 implant designs, with the null hypothesis that there was no inferiority of the ATTUNE knee system.
Materials and Methods

Ethical approval was obtained (NRES Manchester South 14/NW/1330). The trial was designed as a single-center, single-blinded randomized controlled trial comparing the P.F.C. SIGMA and ATTUNE knee implants. The trial protocol was previously published and registered (ISRCTN10345709). Inclusion and exclusion criteria are illustrated in Table I.

Data Collection

Demographic data included age, sex, body mass index, and medical comorbidities. Clinical data included tourniquet time, American Society of Anesthesiologists (ASA) classification, hospital length of stay, and preoperative and postoperative hemoglobin. Complications were recorded, such as superficial and deep infection, thromboembolic events, and return to the operating room for a procedure (e.g., a wound irrigation or joint manipulation) for the involved limb during the study.

Clinical and Functional Outcome Measures

The primary outcome measure was the change in the Oxford Knee Score (OKS) between baseline and 3 months; the time points of 6 weeks and 1 year were also examined. The secondary joint-specific outcome measures included the Oxford Knee Score-Activity and Participation Questionnaire (OKS-APQ) and the Patient Knee Implant Performance (PKIP) score. The secondary outcomes for general quality-of-life outcome measures included the Short Form-36 (SF-36) and the 5-Level EuroQol 5 Dimensions (EQ-5D-5L). The use of these questionnaires is well described in the literature, as are their validity and responsiveness to change. All secondary outcomes were also evaluated at baseline, 6 weeks, 3 months, and 1 year.

Clinical outcomes recorded included preoperative and postoperative range of motion of the affected knee joint as measured with a goniometer and a Pain Numeric Rating Scale (NRS) (not the visual analog scale [VAS] for pain that was listed in the registry data in error) on a scale of 0 (no pain) to 10 (worst pain). Table II illustrates the time points during the trial at which each patient-reported outcome measure and clinical outcome measure was recorded. Radiographic assessment using the Centricity Enterprise (GE Healthcare) Picture Archiving and Communication System (PACS) was utilized to document the severity of preoperative osteoarthritis as measured using the Kellgren-Lawrence grading.

Surgical Technique

The operating surgeons were either consultants (n = 8) or senior fellows (n = 3) with extensive experience using the P.F.C. SIGMA system. Surgeons were asked to perform a minimum of 5 ATTUNE cruciate-retaining TKRs prior to operating on patients in the study to ensure familiarity with the system. It was planned for patients to undergo an enhanced recovery protocol per departmental guidelines (joint education classes, spinal anesthesia with local infiltration, and early mobilization). If patients declined spinal anesthesia or the spinal anesthetic was unable to be administered, the surgical procedure was performed under general anesthesia with local infiltration and with or without femoral nerve blockade. All patients received perioperative antibiotics and anticoagulation per departmental protocols.

Patients underwent TKA under a tourniquet, through a midline incision and medial parapatellar approach, with a cemented, fixed-bearing, cruciate-retaining implant. A measured resection technique was utilized and component cementation was performed in 2 independent mixes. All surgical procedures were planned to be undertaken without patellar resurfacing; however, surgeons were advised to resurface the patella if they believed that this was indicated. Wound closure was performed as per the operating surgeon’s preferred technique, and the wound was dressed using AQUACEL dressings (Convatec) and a wool and crepe bandage. Patients were mobilized once the effects of regional anesthesia had subsided, and all patients underwent physiotherapy per departmental protocols.

| TABLE I Inclusion and Exclusion Criteria |
|------------------------------------------|
| **Inclusion Criteria**                   | **Exclusion Criteria**                          |
| Male or female sex between 22 and 90 years of age, inclusive | Patient has a diagnosis of inflammatory or posttraumatic osteoarthritis |
| A diagnosis of primary osteoarthritis of the knee | Severe bone defects or deformity that will require augmentation with a bone graft, an augmented prosthesis, or a constrained device |
| Primary varus osteoarthritis deformity | Valgus osteoarthritis |
| Stable collateral ligaments at the time of the preoperative clinical examination | Previous patellectomy |
| Patient is a candidate for routine primary knee arthroplasty (cruciate-retaining with no patellar resurfacing) in line with the manufacturer’s guidelines | Patient has a contralateral TKR that is a P.F.C. SIGMA or ATTUNE implant |
| Subject is able to give consent to procedure | Patient has a poorly functioning or symptomatic contralateral or ipsilateral total hip replacement |
| | Previous lower-limb amputation on either limb |
| | Previous fractures, osteotomy, or surgical procedure to the knee that required metal implantation and/or ligament reconstruction |
| | Neurogenic cause for arthritis in the knee or associated neurological symptoms in the lower limb referred from the spine |
Recruitment and Randomization

A total of 162 patients were recruited and randomized to the study. The Consolidated Standards of Reporting Trials (CONSORT) diagram in Figure 1 illustrates the study progression. Twelve operations were cancelled for anesthetic reasons after randomization. These 12 patients were excluded from the study and their randomization numbers and allocations were discarded. This left a total of 150 patients who underwent a surgical procedure. Three patients declined consent to participate. There was no other loss to follow-up.

Results

Outcome Measures

Both groups showed comparable reductions in pain NRS levels at baseline or any postoperative time point when comparing the ATTUNE and P.F.C. SIGMA groups. No patients were randomized to the P.F.C. SIGMA arm. No patients underwent patellar resurfacing.

Statistical Analysis

The study was designed as a noninferiority study, with the primary outcome being the change in OKS between baseline and 3 months. A noninferiority margin in the OKS of 5.0 points was used to calculate the sample size. Based on an estimated standard deviation of 11.6 points and a 2-sided alpha level of 0.05, a sample size of 150 patients was calculated. This was inclusive of a 10% loss of follow-up at each time point to maintain statistical power of 80%. Analyses were performed on an intention-to-treat basis, with missing data dealt with as per the recommendations for each outcome measure. We calculated the mean or median values and the accompanying 95% confidence intervals (CIs), and significance was set at p < 0.05. The primary outcome was analyzed using analysis of covariance (ANCOVA) techniques, which analyzed the 3-month outcome data and included the baseline data as an adjusting covariate. Further analyses were performed using longitudinal analysis methods using linear mixed modeling techniques with the patient identification included as a random effect and treatment included as a fixed effect nested within time, where time was included as a categorical variable. Differences between treatments were measured at each time point, and the results were presented as the difference between means and associated 95% CIs. Statistical analysis was performed using the R statistical package (version 3.6.2, R Foundation for Statistical Computing). Patients and the statistician were blinded as to the allocated treatment arm until all data had been analyzed.

Preoperative and postoperative patient-reported outcome measures are presented in Tables III and IV. When assessing the primary outcome measure, the median (interquartile range [IQR]) change in OKS between baseline and 3 months was 15 points (9, 23 points) in the ATTUNE group and 13 points (8, 22.25 points) in the P.F.C. SIGMA group. An estimated mean difference (and standard error) between groups of −1.748 ± 1.547 points was obtained, with a 95% CI of −4.78 to 1.28 points. The upper limit of the 95% CI was smaller than the noninferiority margin of 5 points, therefore showing noninferiority of the ATTUNE implant.

There were no significant differences between the 2 arms at baseline or at any postoperative time point when comparing the OKS and OKS-APQ. Both groups demonstrated increases in the OKS and OKS-APQ. Both groups demonstrated increases in the OKS and OKS-APQ. The ATTUNE arm showed a lower median (IQR) change in OKS compared to the P.F.C. SIGMA arm (p = 0.929) at baseline, and it was 18.2 points for the ATTUNE group compared with 18.07 points for the P.F.C. SIGMA group (p = 0.865) at 12 months postoperatively. There was no difference in the numbers of patients achieving the minimal clinically important difference from baseline to 1 year postoperatively for the OKS between the ATTUNE and P.F.C. SIGMA groups.
Early Functional Outcomes After Evolutionary Total Knee Arthroplasty

Fig. 1
CONSORT flow diagram. ROM = range of motion.
groups: 66 patients (87%) in the ATTUNE group and 64 patients (86%) in the P.F.C. SIGMA group (p = 0.817). There were also increases in the OKS-APQ scores in both groups from baseline to 12 months postoperatively; the mean OKS-APQ was 9.33 points in the ATTUNE group at baseline, and it was 12.73 points in the P.F.C. SIGMA group (p = 0.446) at 12 months postoperatively. There was an increase in the overall and subset PKIP scores from baseline but no significant difference between the groups.

**Generic Health Outcome Measures: EQ-5D-5L and SF-36**

There was no difference between the 2 groups at baseline when comparing the EQ-5D-5L index scores. The increase in the EQ-5D-5L scores in both groups indicated overall improvement in quality of life; however, there were no significant differences at

| TABLE III Baseline Demographic Characteristics and Preoperative Outcome Scores by Group |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
| Covariate and Level             | ATTUNE (N = 76) | P.F.C. SIGMA (N = 74) | Total (N = 150) | P Value       |
| Side*                           | 34              | 34              | 68              | 1              |
| Left                            | 42              | 40              | 82              | 0.817         |
| Right                           | 36              | 30              | 66              |               |
| Sex*                           | 40              | 44              | 84              |               |
| Grade of surgeon†               | 46 (61%)        | 53 (72%)        | 99              |               |
| Consultant                      | 30 (39%)        | 21 (28%)        | 51              | 0.171         |
| Body mass index† (kg/m²)        | 30.6 (27, 34.5) | 30.5 (27, 35.3) | 0.5             | 0.446         |
| ASA classification†             | 13 (17%)        | 9 (12%)         | 22              | 0.533         |
| I                               | 52 (68%)        | 50 (68%)        | 102             | 0.447         |
| II                              | 11 (15%)        | 15 (20%)        | 26              |               |
| Anesthetic type†                | 74 (97%)        | 72 (97%)        | 146             | 0.533         |
| General anesthesia only         | 2 (3%)          | 1 (1%)          | 3               |               |
| General anesthesia and femoral block | 0 (0%)      | 1 (1%)          | 1               |               |
| Spinal                          | 13.7 (12.78, 14.6) | 13.7 (13, 14.5) | 0.649           |               |
| Preoperative hemoglobin† (g/dL) | 7.11 (6.09 to 8.12) | 6.96 (5.94 to 7.98) | 0.843           |               |
| Knee extension§ (deg)           | 106.71 (103.75 to 109.67) | 103.31 (100.31 to 106.31) | 0.116           |               |
| Knee flexion§ (deg)             | 9.27 (6.69 to 7.84) | 7.18 (6.62 to 7.75) | 0.842           |               |
| Pain VAS§ (0 to 10)              | 18.2 (16.1 to 20.31) | 18.07 (15.96 to 20.17) | 0.929           |               |
| OKS Total§ (points)             | 9.33 (3.15 to 15.5) | 12.73 (6.55 to 18.91) | 0.446           |               |
| PKIP Total§ (points)            | 26.56 (22.9 to 30.22) | 24.54 (20.83 to 28.25) | 0.447           |               |
| PKIP Confidence§ (points)       | 2.81 (2.22 to 3.41) | 2.57 (1.96 to 3.17) | 0.572           |               |
| PKIP Stability§ (points)        | 2.64 (2.02 to 3.26) | 2.45 (1.82 to 3.08) | 0.673           |               |
| PKIP Modify Activities§ (points) | 5.04 (4.29 to 5.8) | 4.89 (4.13 to 5.66) | 0.784           |               |
| PKIP Satisfaction§ (points)     | 1.7 (1.13 to 2.26) | 1.34 (0.77 to 1.91) | 0.390           |               |
| EQ-5D-5L Index§                  | 0.44 (0.39 to 0.5) | 0.42 (0.37 to 0.47) | 0.550           |               |
| SF-36 PCS† (points)             | 33.69 (28.735, 38.415) | 33.5 (28.645, 37.23) | 0.679           |               |
| SF-36 MCS‡ (points)             | 44.795 (39.442, 54.015) | 43.815 (36.193, 53.89) | 0.368           |               |

*The values are given as the number of patients. †The values are given as the number of patients, with the percentage in parentheses. ‡The values are given as the median, with the IQR in parentheses. §The values are given as the mean, with the 95% CI in parentheses.
| Covariate and Level                  | ATTUNE (N = 76) | P.F.C. SIGMA (N = 74) | P Value |
|-------------------------------------|-----------------|-----------------------|---------|
| Tourniquet time* (min)              | 75 (65, 86)     | 66 (55, 77)           | 0.001†  |
| Postoperative hemoglobin* (g/dL)    | 11.55 (10.68, 12.33) | 11.00 (10.40, 12.10) | 0.102   |
| Length of stay* (day)               | 3.00 (2.75, 4.00) | 3.00 (3.00, 4.00)     | 0.168   |
| Knee extension† (deg)               |                 |                       |         |
| 6 weeks                             | 3.55 (2.54 to 4.56) | 3.69 (2.66 to 4.72)   | 0.851   |
| 12 weeks                            | 2.18 (1.17 to 3.20) | 2.15 (1.12 to 3.19)  | 0.968   |
| 1 year                              | 0.31 (−0.73 to 1.34) | 1.03 (−0.01 to 2.07) | 0.333   |
| Knee flexion† (deg)                 |                 |                       |         |
| 6 weeks                             | 99.80 (96.84 to 102.76) | 99.41 (96.40 to 102.43) | 0.856   |
| 12 weeks                            | 106.30 (103.33 to 109.28) | 104.89 (101.86 to 107.92) | 0.516   |
| 1 year                              | 109.01 (105.99 to 112.03) | 108.09 (105.06 to 111.12) | 0.673   |
| Pain VAS† (0 to 10)                 |                 |                       |         |
| 6 weeks                             | 3.80 (3.20 to 4.39) | 3.89 (3.29 to 4.48)   | 0.837   |
| 12 weeks                            | 3.23 (2.65 to 3.82) | 3.29 (2.71 to 3.87)  | 0.896   |
| 1 year                              | 2.48 (1.90 to 3.06) | 1.97 (1.40 to 2.55)  | 0.224   |
| OKS Total‡ (points)                 |                 |                       |         |
| 6 weeks                             | 27.39 (25.22 to 29.57) | 27.05 (24.88 to 29.22) | 0.826   |
| 12 weeks                            | 33.85 (31.71 to 36.00) | 32.23 (30.07 to 34.39) | 0.298   |
| 1 year                              | 38.03 (35.91 to 40.14) | 36.28 (34.16 to 38.40) | 0.254   |
| OKS-APO‡ (points)                   |                 |                       |         |
| 6 weeks                             | 28.60 (22.15 to 35.04) | 29.74 (23.20 to 36.28) | 0.807   |
| 12 weeks                            | 47.46 (41.09 to 53.82) | 43.14 (36.81 to 49.47) | 0.347   |
| 1 year                              | 56.16 (49.99 to 62.33) | 58.94 (52.76 to 65.13) | 0.533   |
| PKIP Total‡ (points)                |                 |                       |         |
| 6 weeks                             | 50.73 (47.07 to 54.39) | 51.00 (47.29 to 54.70) | 0.920   |
| 12 weeks                            | 57.00 (53.34 to 60.66) | 56.83 (53.12 to 60.53) | 0.948   |
| 1 year                              | 60.63 (56.95 to 64.30) | 61.00 (57.30 to 64.71) | 0.888   |
| PKIP Confidence‡ (points)           |                 |                       |         |
| 6 weeks                             | 4.96 (4.36 to 5.55) | 5.28 (4.68 to 5.89)   | 0.451   |
| 12 weeks                            | 5.96 (5.36 to 6.55) | 5.88 (5.28 to 6.49)  | 0.866   |
| 1 year                              | 6.57 (5.97 to 7.17) | 6.72 (6.12 to 7.33)  | 0.726   |
| PKIP Stability‡ (points)            |                 |                       |         |
| 6 weeks                             | 5.45 (4.82 to 6.07) | 5.65 (5.01 to 6.28)   | 0.659   |
| 12 weeks                            | 6.18 (5.56 to 6.80) | 6.19 (5.56 to 6.82)  | 0.978   |
| 1 year                              | 6.80 (6.18 to 7.42) | 7.18 (6.54 to 7.81)  | 0.408   |
| PKIP Modify Activities‡ (points)    |                 |                       |         |
| 6 weeks                             | 5.40 (4.64 to 6.16) | 5.32 (4.55 to 6.08)   | 0.883   |
| 12 weeks                            | 5.79 (5.04 to 6.55) | 5.68 (4.92 to 6.45)  | 0.836   |
| 1 year                              | 5.58 (4.83 to 6.34) | 5.28 (4.51 to 6.04)  | 0.581   |
| PKIP Satisfaction‡ (points)         |                 |                       |         |
| 6 weeks                             | 5.61 (5.05 to 6.18) | 5.64 (5.06 to 6.21)   | 0.959   |
| 12 weeks                            | 6.52 (5.96 to 7.09) | 6.26 (5.79 to 6.94)  | 0.702   |
| 1 year                              | 6.71 (6.15 to 7.28) | 6.83 (6.26 to 7.40)  | 0.769   |
| EQ-5D Index‡ (points)               |                 |                       |         |
| 6 weeks                             | 0.67 (0.62 to 0.72) | 0.63 (0.57 to 0.68)   | 0.279   |
| 12 weeks                            | 0.73 (0.67 to 0.78) | 0.67 (0.62 to 0.73)  | 0.164   

*continued*
the mean OKS increase was 15.4 points (range, 2 to 26 points).

Clinically important difference for the OKS at the developed a pulmonary embolism) had achieved the minimal

tions, 9 of 10 patients (1 patient in the P .F.C. SIGMA group

operative popliteal artery injury that required vascular repair

level. One patient in the ATTUNE group sustained an intra-

surgical treatment required. Three patients with progressive stiffness (2

were treated with oral antibiotics with no subsequent antibiotic or sur-

fi

ical infection (1 with the ATTUNE implant and 2 with the P .F.C. SIGMA implant), all

with the ATTUNE knee implant. Ranawat et al.

sizes.

nonrandomized and had signi

cantly less patellofemoral crepitus; however, the retro-

Discussion

This study did not show any inferiority of the ATTUNE implant

compared with the P .F.C. SIGMA implant at 3 months post-

operatively and did not show any differences at any other time

point. Patient recruitment and retention met the target set by the

power analysis and there was minimal loss to follow-up. Both

groups showed significant and comparable improvements in all

outcome measures in the first year postoperatively, with no signi-

ificant implant-related complications. Both the EQ-5D-5L and

SF-36 generic health measures showed consistent patient satisfac-

tion and health improvements in both groups, further highlighting

the success of the knee replacement. Tourniquet time was found to

be significantly lower in the P .F.C. SIGMA group (p = 0.001); however, an ANCOVA performed to assess the 12-month follow-

up data while adjusting for the baseline OKS showed that tourni-

quet time had no measurable impact on the OKS (p = 0.825).

Surgeon and industry-led collaborations have led to

many advancements in the understanding of knee arthroplasty

with respect to biomechanics and material science, with sub-

sequent implant evolution. Early studies following the launch

of the ATTUNE prosthesis in 2013 demonstrated improved

patient-reported outcome measures, greater range of motion,

reduced pain scores, and a shorter length of stay compared with

other leading knee systems42. However, these studies were

nonrandomized and had significant bias and small sample

sizes.

Several studies have previously shown improved results

when using the ATTUNE knee implant. Ranawat et al.17 reported

on 100 consecutive ATTUNE knee implants that were matched

to 100 P .F.C. SIGMA implants. At the 2-year follow-up, there

were no differences found in the Knee Society Scores (KSS) or

patient satisfaction; however, there was a reduced incidence of

anterior knee pain and patellofemoral joint crepitation in the

ATTUNE group, postulated to be a result of improved implant

patellofemoral kinematics and trochlear design. Martin et al.16

compared 2 cohorts of patients with the P .F.C. SIGMA implant

(n = 1,165) and patients with the ATTUNE implant (n = 728) and

found that cases with a posterior-stabilized ATTUNE TKR had

significantly less patellofemoral crepitus; however, the retro-

spective design of the study and the nonstandardized method of

diagnosing patellofemoral crepitus were significant limitations.

Indelli et al.19 compared 100 matched patients with a posterior-


TABLE IV (continued)

| Covariate and Level | ATTUNE (N = 76) | P.F.C. SIGMA (N = 74) | P Value |
|---------------------|----------------|----------------------|---------|
| 1 year              | 0.77 (0.71 to 0.82) | 0.71 (0.66 to 0.76) | 0.112   |
| SF-36 PCS* (points) | 44.795 (39.442, 54.015) | 43.815 (36.193, 53.89) | 0.529   |
| 1 year              | 54.835 (44.46, 59.6) | 53.845 (44.39, 59.325) | 0.490   |

*The values are given as the median, with the IQR in parentheses. †Significant. ‡The values are given as the mean, with the 95% CI in parentheses.

Complications

Complications observed during the study are outlined in Table V. In the ATTUNE group, there were 2 cases of thromboembolic events, compared with 1 case in the P .F.C. SIGMA group. All cases were treated with anticoagulation as per trust guidelines. One patient in the ATTUNE group required a hematoma irrigation at 4 days postoperatively. There were 3 superficial infections (1 with the ATTUNE implant and 2 with the P .F.C. SIGMA implant), all treated with oral antibiotics with no subsequent antibiotic or surgical treatment required. Three patients with progressive stiffness (2 with the ATTUNE implant and 1 with the P .F.C. SIGMA implant) underwent a manipulation under anesthesia within 3 months of the index procedure and recovered knee flexion to a satisfactory level. One patient in the ATTUNE group sustained an intraoperative popliteal artery injury that required vascular repair within 24 hours of the index procedure. Despite the complications, 9 of 10 patients (1 patient in the P .F.C. SIGMA group developed a pulmonary embolism) had achieved the minimal clinically important difference for the OKS at the final review; the mean OKS increase was 15.4 points (range, 2 to 26 points).

| Complication                | ATTUNE | P.F.C. SIGMA |
|-----------------------------|--------|--------------|
| Deep venous thrombosis      | 1      | 0            |
| Pulmonary embolism          | 1      | 1            |
| Hematoma irrigation         | 1      | 0            |
| Superficial infection       | 1      | 2            |
| Deep infection              | 0      | 0            |
| Vascular injury             | 1      | 0            |
| Stiffness requiring         | 2      | 1            |
| manipulation under anesthesia|        |              |

*The values are given as the number of patients.
stabilized ATTUNE implant and 100 patients with a posterior-stabilized P.F.C. SIGMA implant. Despite significant increases in knee flexion and reduced anterior knee pain in the ATTUNE group, no other clinical or patient-reported outcome measurement showed any significant difference. It should be noted that only 1 surgeon performed the ATTUNE knee implantations compared with 2 surgeons in the P.F.C. SIGMA group, with no crossover, and there was an increased use of a lateral release in the P.F.C. SIGMA group, which could have had a significant bearing on the clinical outcomes and subsequent comparison, especially when comparing the rates of anterior knee pain. Carey and Harty21 retrospectively reviewed 21 patients who underwent bilateral TKA (with 1 ATTUNE implant and 1 P.F.C. SIGMA implant) performed in staged procedures. The authors reported a significant increase in the patient-reported outcome measures in the ATTUNE group; however, different patient-reported outcome measure assessments were utilized for the P.F.C. SIGMA and ATTUNE groups, and this, coupled with the small sample size, presented significant limitations. Giaretta et al.21 reported on 228 primary cemented ATTUNE TKRs, showing improvements on the Knee injury and Osteoarthritis Outcome Score (KOOS) and OKS; however, there was no comparator group in this study. Song et al.22 compared 300 patients with the ATTUNE implant with 300 matched patients with the P.F.C. SIGMA implant in a retrospective study in patients with a posterior-stabilized design with patellar resurfacing. Significant improvements were reported in the posterior Knee Society Knee Score and range of motion; however, no difference was reported in the Knee Society Function Score.

In contrast, several studies have found no improvements in outcomes with the ATTUNE implant. Kaptein et al.25 performed a randomized controlled trial that did not show any difference in postoperative patient-reported outcome measures; however, these were secondary outcome measures, as the study was primarily powered for radiographic assessment and not patient-reported outcome measure assessment. Furthermore, this study included patients with inflammatory arthritis, patellar resurfacing was performed, and preoperative severity and alignment were not discussed. Behrend et al.26 found no differences in clinical outcomes or patient-reported outcome measures at 1 year postoperatively when comparing the ATTUNE implant with the LCS implant (DePuy Synthes). Molloy et al.27 and Chua et al.28 found no difference in outcome measures between the ATTUNE group and the P.F.C. SIGMA group.

There were several limitations to this study. This study involved a single, high-volume institution, which may limit the generalizability of the results to other orthopaedic departments in other hospitals. However, multiple surgeons performed the procedures and surgeons used their own techniques in performing the surgical procedure, albeit using a measured resection technique. The study only assessed patients with varus-pattern osteoarthritis, and all patients underwent a surgical procedure with a cruciate-retaining, fixed-bearing design with no patellar resurfacing. Although this is the most common indication and construct in our institution, the results cannot be extrapolated to other fixed-bearing, cruciate-retaining implants or types of osteoarthritis. The goal of the trial was to assess early functional results, and we cannot comment on longer-term results or revision rates without longer follow-up.

Given that the focus of our study was early functional outcomes, we believe that the calculated sample size and follow-up duration were appropriate. The 5-year cumulative revision rates for the ATTUNE implant are in line with those of the P.F.C. SIGMA implant22, and proving any marginal differences in revision rates would require longer follow-up studies with thousands of patients and arguably would not be an appropriate use of public health funding resources.

With multiple studies showing no significant advantage of one implant over another, the question remains as to how patient satisfaction can be improved following TKA. A recent review highlighted that improved kinematics of a knee implant does not necessarily correlate with improved clinical outcomes in the short to medium term.29 This further highlights that multifactorial nature of knee replacement recovery and that implant design is only one of a multitude of factors that need to be addressed along with the soft-tissue component, postoperative rehabilitation, and the psychosocial aspects of the patient. Further studies looking at these factors would be valuable in helping to improve patient outcomes following TKA.

In conclusion, this study showed no inferiority of the ATTUNE implant following TKA when comparing early function with that of the P.F.C. SIGMA implant. The results only reflect short-term outcomes; however, we recommend that implant innovation should continue, with the implantation of new devices being performed within the context of randomized controlled trials to ensure their safety and efficacy. Further studies into TKA outcomes should examine the influence of patient characteristics, psychosocial factors, and rehabilitation modalities.

### References

1. Behrend et al.25 performed a randomized controlled trial that did not show any difference in postoperative patient-reported outcome measures; however, these were secondary outcome measures, as the study was primarily powered for radiographic assessment and not patient-reported outcome measure assessment. Furthermore, this study included patients with inflammatory arthritis, patellar resurfacing was performed, and preoperative severity and alignment were not discussed. Behrend et al.26 found no differences in clinical outcomes or patient-reported outcome measures at 1 year postoperatively when comparing the ATTUNE implant with the LCS implant (DePuy Synthes).

2. Molloy et al.27 and Chua et al.28 found no difference in outcome measures between the ATTUNE group and the P.F.C. SIGMA group.

3. There were several limitations to this study. This study involved a single, high-volume institution, which may limit the generalizability of the results to other orthopaedic departments in other hospitals. However, multiple surgeons performed the procedures and surgeons used their own techniques in performing the surgical procedure, albeit using a measured resection technique. The study only assessed patients with varus-pattern osteoarthritis, and all patients underwent a surgical procedure with a cruciate-retaining, fixed-bearing design with no patellar resurfacing. Although this is the most common indication and construct in our institution, the results cannot be extrapolated to other fixed-bearing, cruciate-retaining implants or types of osteoarthritis. The goal of the trial was to assess early functional results, and we cannot comment on longer-term results or revision rates without longer follow-up.

4. Given that the focus of our study was early functional outcomes, we believe that the calculated sample size and follow-up duration were appropriate. The 5-year cumulative revision rates for the ATTUNE implant are in line with those of the P.F.C. SIGMA implant, and proving any marginal differences in revision rates would require longer follow-up studies with thousands of patients and arguably would not be an appropriate use of public health funding resources.

5. With multiple studies showing no significant advantage of one implant over another, the question remains as to how patient satisfaction can be improved following TKA. A recent review highlighted that improved kinematics of a knee implant does not necessarily correlate with improved clinical outcomes in the short to medium term. This further highlights that multifactorial nature of knee replacement recovery and that implant design is only one of a multitude of factors that need to be addressed along with the soft-tissue component, postoperative rehabilitation, and the psychosocial aspects of the patient. Further studies looking at these factors would be valuable in helping to improve patient outcomes following TKA.

6. In conclusion, this study showed no inferiority of the ATTUNE implant following TKA when comparing early function with that of the P.F.C. SIGMA implant. The results only reflect short-term outcomes; however, we recommend that implant innovation should continue, with the implantation of new devices being performed within the context of randomized controlled trials to ensure their safety and efficacy. Further studies into TKA outcomes should examine the influence of patient characteristics, psychosocial factors, and rehabilitation modalities.
Early Functional Outcomes After Evolutionary Total Knee Arthroplasty

References

1. Price AJ, Alvand A, Troelsen A, Katz JN, Hooper G, Gray A, Carr A, Beard D. Knee replacement. Lancet. 2018 Nov 3;392(10158):1672-82.

2. National Joint Registry. NJR 16th annual report. 2019. Accessed 2020 Jun 5. https://reports.njrcentre.org.uk/downloads

3. Scott CE, Howie CR, MacDonald D, Blantz LC. Predicting dissatisfaction following total knee replacement: a prospective study of 1217 patients. J Bone Joint Surg Br. 2010 Sep;92(9):1253-8.

4. Causero A, Di Benedetto P, Beltrame A, Gisonni R, Cainero V, Pagano M. Design evolution in total knee replacement: which is the future? Acta Biomed. 2014 Sep 24;85(Suppl 2):5-19.

5. Dalury DF, Gonzales RA, Adams MJ, Gruen TA, Trier K. Midterm results with the PFC Sigma total knee arthroplasty system. J Arthroplasty. 2008 Feb;23(2):175-81. Epub 2007 Oct 24.

6. DePuy Synthes. ATTUNE Knee System. 2012. Accessed 2020 Jul 16. https://www.depuyosynthes.com/hcp/knee/products/qs/ATTUNE-Knee-System

7. Panchani S, Gambhir AK, Pavlou G, Jones HW, Board TN. A comparison of patient reported outcome measures following total knee replacement with either the Depuy Synthes ATTUNE™ or Depuy Synthes PFC™ total knee replacement systems: a single blinded randomised controlled trial study protocol. Clin Res Trials. 2015;1(2):51-4.

8. Murray DW, Fitzpatrick R, Rogers K, Pandit H, Beard DJ, Carr AJ, Dawson J. The use of the Oxford hip and knee scores. J Bone Joint Surg Br. 2007 Aug;89(8):1010-4.

9. Dawson J, Beard DJ, McKibbin H, Harris K, Jenkinson C, Price AJ. Development of a patient-reported outcome measure of activity and participation (the OKS-APQ) to supplement the Oxford knee score. Bone Joint J. 2014 Mar;96-B(3):332-8.

10. Coles T, Williams V, Dwyer K, Mordini M. Psychometric evaluation of the patient’s knee implant performance questionnaire. Value Health. 2018 Nov;21(11):1305-12. Epub 2018 Jun 30.

11. Ko Y, Lo NN, Yeo SJ, Yang KY, Yeo W, Chong HC, Thumboo J. Comparison of the responsiveness of the SF-36, the Oxford Knee Score, and the Knee Society Clinical Rating System in patients undergoing total knee replacement. Qual Life Res. 2013 Nov;22(9):2459-9. Epub 2013 Mar 5.

12. Jin X, Al Sayah F, Oinhmaa A, Marshall DA, Johnson JA. Responsiveness of the EQ-5D-3L and EQ-5D-5L in patients following total hip or knee replacement. Qual Life Res. 2019 Sep;28(9):2409-17. Epub 2019 May 14.

13. Gagliese L, Weizblit N, Ellis W, Chan WVS. The measurement of postoperative pain: a comparison of intensity scales in younger and older surgical patients. Pain. 2005 Oct;117(3):412-20.

14. Kohn MD, Sassoon AA, Fernandez ND. Classifications in brief: Kellgren-Lawrence classification of osteoarthritis. Clin Orthop Relat Res. 2016 Aug;474(8):1886-93. Epub 2016 Feb 12.

15. Clement ND, MacDonald D, Simpson AH. The minimal clinically important difference in the Oxford knee score and Short Form 12 score after total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2014 Aug;22(8):1933-9. Epub 2013 Nov 20.

16. DePuy Synthes. ATTUNE system clinical evidence. Accessed 2020 Jul 15. https://www.attuneevidence.com/clinical-evidence

17. Ranawat CS, White PB, West S, Ranawat AS. Clinical and radiographic results of Attune and PFC Sigma Knee Designs at 2-year follow-up: a prospective matched-pair analysis. J Arthroplasty. 2017 Feb;32(2):431-6. Epub 2016 Aug 9.

18. Martin JR, Jennings JM, Watters TS, Levy DL, McNabb DC, Dennis DA. Femoral implant design modification decreases the incidence of patellar crepitus in total knee arthroplasty. J Arthroplasty. 2017 Apr;32(4):1310-3. Epub 2016 Nov 22.

19. Indelli PF, Pipino G, Johnson P, Graceffo A, Marcucci M. Posterior-stabilized total knee arthroplasty: a matched pair analysis of a classic and its evolutionary design. Arthroplast Today. 2016 Aug 21;2(4):193-8.

20. Carey BW, Hardy J. A comparison of clinical- and patient-reported outcomes of the cemented ATTUNE and PFC Sigma fixed bearing cruciate sacrificing knee systems in patients who underwent total knee replacement with both prostheses in opposite knees. J Orthop Surg Res. 2018 Mar 15;13(1):54.

21. Giaretta S, Berti M, Micheloni GM, Ceccato A, Marangoni F, Momoli A. Early experience with the ATTUNE total knee replacement system. Acta Biomed. 2019 Oct 29;90(12-S):98-103.

22. Song SJ, Kang SG, Park CH, Bae DK. Comparison of clinical results and risk of patellar injury between Attune and PFC Sigma knee systems. Knee Surg Relat Res. 2018 Dec 1;3(4):334-40.

23. Kaptein BL, den Hollander P, Thomassen B, Fiocco M, Nellissen RGH, A randomized controlled trial comparing tibial migration of the ATTUNE cemented cruciate-retaining knee prosthesis with the PFC-Sigma design. Bone Joint J. 2020 Sep;102-B(9):1158-66.

24. Behrend H, Zdravkovic V, Bösch M, Hochreiter B. No difference in joint awareness after TKA: a matched-pair analysis of a classic implant and its evolutionary design. Knee Surg Sports Traumatol Arthrosc. 2019 Jul;27(7):2124-9. Epub 2019 Feb 14.

25. Molloy IB, Keeney BJ, Sparks MB, Paddock NG, Koening KM, Moschetti WE, Jevsevar DS. Short term patient outcomes after total knee arthroplasty: Does the implant matter? Knee. 2019 Jun;26(3):687-99. Epub 2019 Mar 23.

26. Chua JL, Goh GSH, Lo NN, Yeo SJ. Modern TKA implants are equivalent to traditional TKA implants in functional and patellofemoral joint-related outcomes. Knee Surg Sports Traumatol Arthrosc. 2019 Apr;27(4):1116-23. Epub 2018 Sep 28.

27. Australian Orthopaedic Association National Joint Replacement Registry. Hip, knee & shoulder arthroplasty. Annual report 2020. 2020. Accessed 2021 Feb 4. https://aoanjrr.sahmri.com/annual-reports-2020

28. Ng JWG, Bloch BV, James PJ. Sagittal radius of curvature, trochlea design and ultracongruent insert in total knee arthroplasty. EFORT Open Rev. 2019 Aug 7;4(8):519-24.